Amgen: Dermatitis, Atopic trials

The registry lists 15 Dermatitis, Atopic studies with Amgen as lead sponsor. 0 are open to participants now and 10 have results posted.

Early Phase 1 1Phase 1 4Phase 2 2Phase 3 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsCompletedNCT06268860Phase 1Results posted
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)CompletedNCT05899816Phase 3Results posted
• A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)CompletedNCT05724199Phase 3Results posted
• A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)CompletedNCT05704738Phase 3Results posted
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)CompletedNCT05651711Phase 3Results posted
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)CompletedNCT05633355Phase 3Results posted
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)CompletedNCT05398445Phase 3Results posted
• A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic DermatitisTerminatedNCT03809663Phase 2Results posted
• Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic DermatitisCompletedNCT02087943Phase 2Results posted
• Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic DermatitisCompletedNCT00757042Phase 1Results posted
• A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy ParticipantsCompletedNCT06438263Phase 1
• A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic DermatitisCompletedNCT06224192Phase 3
• A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese ParticipantsCompletedNCT06214481Phase 1
• Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic DermatitisCompletedNCT05891119Early Phase 1
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)TerminatedNCT05882877Phase 3